NCT05463068Phase 3Completed

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Study sponsor: Novavax

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-08-17Actual

Enrollment · participants911Actual

Source updated2026-04-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

COVID-19; SARS-CoV-2 Infection

Treatments or interventions studied

NVX-Cov2373DrugAlso known as SARS-CoV-2 rS/Matrix-M Adjuvant

Primary outcomes · main study measures

measure: Serum Immunoglobulin G (IgG) Antibody Levels to the SARS-CoV-2 Spike Protein Expressed as Geometric Mean ELISA Unit [GMEUs]; description: Serum Immunoglobulin G (IgG) geometric mean ELISA unit concentrations (GMEU/mL) to the SARS-CoV-2 spike protein at Day 29 in each treatment arm.; timeFrame: Baseline (Day 1) and Day 29

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history